Co-Authors
This is a "connection" page, showing publications co-authored by JAMES WELSH and NAHUM PUEBLA-OSORIO.
Connection Strength
4.323
-
Enhanced tumor control and survival in preclinical models with adoptive cell therapy preceded by low-dose radiotherapy. Front Oncol. 2024; 14:1407143.
Score: 0.987
-
Superior antitumor immune response achieved with proton over photon immunoradiotherapy is amplified by the nanoradioenhancer NBTXR3. J Nanobiotechnology. 2024 Oct 01; 22(1):597.
Score: 0.246
-
Correction: Novel engineered IL-2 Nemvaleukin alfa combined with PD1 checkpoint blockade enhances the systemic anti-tumor responses of radiation therapy. J Exp Clin Cancer Res. 2024 Sep 10; 43(1):256.
Score: 0.245
-
Inhibition of MER proto-oncogene tyrosine kinase by an antisense oligonucleotide enhances treatment efficacy of immunoradiotherapy. J Exp Clin Cancer Res. 2024 Mar 06; 43(1):70.
Score: 0.237
-
Nanoparticle-enhanced proton beam immunoradiotherapy drives immune activation and durable tumor rejection. JCI Insight. 2023 06 22; 8(12).
Score: 0.225
-
Durable control of metastases in an HLA-A2+ patient with refractory melanoma after low-dose radiotherapy in combination with MAGE-A4 T cell therapy: a case report. Melanoma Res. 2023 08 01; 33(4):332-337.
Score: 0.225
-
Inhibition of STAT6 with Antisense Oligonucleotides Enhances the Systemic Antitumor Effects of Radiotherapy and Anti-PD-1 in Metastatic Non-Small Cell Lung Cancer. Cancer Immunol Res. 2023 04 03; 11(4):486-500.
Score: 0.222
-
NBTXR3 improves the efficacy of immunoradiotherapy combining nonfucosylated anti-CTLA4 in an anti-PD1 resistant lung cancer model. Front Immunol. 2022; 13:1022011.
Score: 0.216
-
Pulsed radiotherapy to mitigate high tumor burden and generate immune memory. Front Immunol. 2022; 13:984318.
Score: 0.215
-
Combining a nanoparticle-mediated immunoradiotherapy with dual blockade of LAG3 and TIGIT improves the treatment efficacy in anti-PD1 resistant lung cancer. J Nanobiotechnology. 2022 Sep 19; 20(1):417.
Score: 0.214
-
High Plus Low Dose Radiation Strategy in Combination with TIGIT and PD1 Blockade to Promote Systemic Antitumor Responses. Cancers (Basel). 2022 Jan 03; 14(1).
Score: 0.204
-
Novel Use of Low-Dose Radiotherapy to Modulate the Tumor Microenvironment of Liver Metastases. Front Immunol. 2021; 12:812210.
Score: 0.203
-
Pulsed Radiation Therapy to Improve Systemic Control of Metastatic Cancer. Front Oncol. 2021; 11:737425.
Score: 0.199
-
Considerations for Clinical Trials Testing Radiotherapy Combined With Immunotherapy for Metastatic Disease. Semin Radiat Oncol. 2021 07; 31(3):217-226.
Score: 0.197
-
Addition of TLR9 agonist immunotherapy to radiation improves systemic antitumor activity. Transl Oncol. 2021 Feb; 14(2):100983.
Score: 0.189
-
Use of Multi-Site Radiation Therapy for Systemic Disease Control. Int J Radiat Oncol Biol Phys. 2021 02 01; 109(2):352-364.
Score: 0.185
-
Novel engineered IL-2 Nemvaleukin alfa combined with PD1 checkpoint blockade enhances the systemic anti-tumor responses of radiation therapy. J Exp Clin Cancer Res. 2024 Sep 02; 43(1):251.
Score: 0.061
-
Bone morphogenetic proteins, activins, and growth and differentiation factors in tumor immunology and immunotherapy resistance. Front Immunol. 2022; 13:1033642.
Score: 0.054